FOXO4-DRI Protocol Guide
FOXO4-DRI is a D-retro-inverso peptide designed to selectively eliminate senescent (aged, non-dividing) cells. It works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, freeing p53 to trigger targeted apoptosis while sparing healthy tissue. Published in Cell (2017) by Baar et al., FOXO4-DRI restored fitness, fur density, and renal function in naturally aged mice. This protocol covers reconstitution from a 10mg vial, subcutaneous dosing at 500mcg three times per week, cycling recommendations, and stacking with other longevity compounds.
Protocol Overview
- Compound
- FOXO4-DRI (D-Retro-Inverso FOXO4 Peptide)
- Category
- Senolytic / Anti-Aging Peptide
- Mechanism
- Disrupts FOXO4-p53 binding in senescent cells, releasing p53 to trigger selective apoptosis of aged cells while sparing healthy dividing cells
- Structure
- D-retro-inverso peptide (protease-resistant mirror-image)
- Half-Life
- Extended (D-amino acid configuration resists proteolysis)
- Vial Size
- 10mg lyophilized powder
- Route
- Subcutaneous injection
- Frequency
- 3x per week (Mon/Wed/Fri)
- Cycle Length
- 4-6 weeks on, 8-12 weeks off
Dosing Protocol
| Protocol | Dose | Frequency | Route | Duration |
|---|---|---|---|---|
| Standard Senolytic | 500 mcg | 3x/week (M/W/F) | Subcutaneous | 4-6 weeks |
| Conservative Start | 200 mcg | 3x/week (M/W/F) | Subcutaneous | 2 weeks, then increase |
| Intensive Cycle | 1 mg | 3x/week (M/W/F) | Subcutaneous | 3-4 weeks |
Key principle: Senolytic protocols are cyclical. Clearing senescent cells requires time for the immune system to process apoptotic debris and for stem cells to regenerate tissue. Extended breaks between cycles are essential.
Reconstitution Instructions
Materials Needed
- FOXO4-DRI 10mg lyophilized vial
- Bacteriostatic water (2mL)
- 3mL mixing syringe (18-20ga)
- Insulin syringes (29-31ga) for dosing
- Alcohol swabs
Reconstitution Steps
- Clean vial stopper with alcohol
- Draw 2mL bacteriostatic water
- Inject slowly down the vial wall
- Gently swirl (never shake)
- Wait 5 minutes for full dissolution
- Concentration: 5,000 mcg/mL
| Dose | Volume (2mL recon) | Insulin Syringe |
|---|---|---|
| 100 mcg | 0.02 mL | 2 units |
| 200 mcg | 0.04 mL | 4 units |
| 500 mcg | 0.10 mL | 10 units |
| 1,000 mcg (1mg) | 0.20 mL | 20 units |
Administration Guide
Injection Sites
- Abdomen: Primary site, rotate quadrants
- Thigh: Outer thigh, alternate sides
- Upper arm: Back of arm, alternate
Timing & Storage
- Timing: Morning administration preferred
- Schedule: Monday, Wednesday, Friday
- Storage (reconstituted): Refrigerate 2-8°C, use within 30 days
- Vial duration: ~33 days at 500mcg 3x/week
- Do not freeze reconstituted solution
Expected Timeline
Side Effects & Monitoring
Common Side Effects
- Mild flu-like symptoms during initial clearance (transient)
- Injection site irritation (mild)
- Temporary fatigue as immune system processes debris
- Mild gastrointestinal changes (uncommon)
Side effects are generally related to the immune response to senescent cell clearance and resolve as the body adjusts.
Precautions
- No human clinical trial data yet (animal studies only)
- Theoretical risk of depleting beneficial senescent cells needed for wound healing
- Avoid during active wound healing or surgery recovery
- Not recommended during pregnancy or breastfeeding
- D-amino acid structure is protease-resistant - effects may be prolonged
Stacking Recommendations
Compatible Compounds
- Epithalon: Telomere maintenance after senescent cell clearance
- NAD+: Cellular energy to support tissue regeneration
- GHK-Cu: Tissue remodeling and gene expression reset
- MOTS-c: Mitochondrial support during cellular turnover
- Thymosin Alpha-1: Immune support for clearance processes
Popular Stacks
- Full Longevity: FOXO4-DRI cycle + Epithalon cycle (sequential)
- Cellular Reset: FOXO4-DRI + NAD+ + GHK-Cu
- Anti-Aging Complete: FOXO4-DRI + Epithalon + MOTS-c
Blood Work Recommendations
| Panel | Markers | Timing |
|---|---|---|
| Inflammatory | CRP, IL-6, TNF-alpha | Baseline, Week 4, post-cycle |
| Basic Panel | CBC, CMP | Baseline, Week 4 |
| Liver/Kidney | ALT, AST, BUN, creatinine | Baseline, Week 4 |
| Senescence Markers | p16INK4a (if available) | Baseline, 1 month post-cycle |
Inflammatory marker reduction is a key indicator of successful senescent cell clearance. Expect CRP and IL-6 to trend downward over the course of the protocol.
Related Tools & Resources
